Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTP488 in Diabetic Nephropathy
NCT00287183Phase 2Completed
- Sponsor
- Pfizer
- Start
- Feb 2006
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic nephropathy (DN) comparing PF-04494700 (TTP488) with Placebo (2 arms). Primary endpoint: Change in urinary albumin-creatinine ratio at Month 6. Started Feb 2006; status: completed.
02
Drugs
azeliragon
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT00287183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00287183.